Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Bayer, Indena Enter Licensing Agreement
March 20, 2000
1 Min Read
WEST HAVEN, Conn.--Milan-based Indena has entered into a licensing agreement with the Bayer Corp.'s Pharmaceutical Division for its IDN 5109 anti-cancer compound and its derivatives. Indena has granted Bayer the exclusive rights to the ingredient.
Indena researches, manufactures and markets active principles derived from plants for use in pharmaceutical, health food and cosmetics applications. The agreement will be effective once the United States government has granted approval.
You May Also Like